PUBLICATIONS

 

2019

  • Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019 (in press)
  • Kenny TC, Craig AJ, Villanueva A, Germain D. Mitohormesis primes tumor invasion and metastasis. Cell Reports 2019 (in press)
  • DeRossi C, Bambino K, Morrison J, Sakarin I, Villacorta-Martin C, Zhang C, Ellis JL, Fiel MI, Ybanez M, Lee YA, Huang KL, Yin C, Sakaguchi TF, Friedman SL, Villanueva A, Chu J. Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology 2019 (in press)
  • Puigvehi M, Moctezuma C, Villanueva A, Llovet JM. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP reports 2019 (in press)
  • Slocum E, Craig A, Villanueva A, Germain D. Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. Breast Cancer Res. 2019 (in press)
  • Yu JX, Craig A, Duffy M, Villacorta-Martin C, Miguela V, Ruiz-de-Galarreta M, Scopton AP, Silber L, Maldonado AY, Rialdi A, Guccione E, Lujambio A*, Villanueva A, Dar AC. Mol Cancer Ther 2019 (in press)
  • Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced hepatocellular carcinoma: Role of PFS as a surrogate of survival. J Hepatol 2019 (in press)
  • Martins-Filho SN, Alves VAF, Wakamatsu A, Maeda M, Craig AJ, Villacorta-Martin C, D’Avola D, Labgaa I, Carrilho FJ, Thung SN, Villanueva A. A phenotypic map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. Histopathology 2019 (in press)

2018

  • von Felden J, Craig AJ, Villanueva A. Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. Oncoscience. 2018 (in press)
  • D’Avola D, Villacorta-Martin C, Martins-Filho SN, Craig AJ, Labgaa I, von Felden J, Allette K, Bonaccorso A, Tabrizian P, Hartmann BN, Sebra R, Schwartz M, Villanueva A. High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. Sci Rep 2018 (in press).
  • Labgaa I*, Villacorta-Martin C*, D’Avola D, Craig AJ, von Felden J, Martins-Filho S, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018 (in press).
  • Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau G, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhag Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gene E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Sole M, Thung S, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 2018 (in press).

2017

  • Villacorta-Martin C, Craig AJ, Villanueva A. Divergent evolutionary trajectories in transplanted tumor models. Nat Genet. 2017 Oct 27;49(11):1565-1566.
  • Craig AJ, von Felden J, Villanueva A. Molecular profiling of liver cancer heterogeneity. Discov Med. 2017;24(131):117-125.
  • Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J Hepatol. 2017;67(6):1222-1231
  • Chiang DY, Villanueva A. Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation? J Hepatol. 2017;67(5):893-895.
  • Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 2017;153(3):812-826.
  • Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017;66(5):952-961.
  • Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Sole M, Domingo-Domenech J, Villanueva A, Llovet JM. Tumour initiating cells and IGF/FGF signaling contribute to sorafenib resistance in hepatocellular carcinoma. Gut 2017;66:952-961
  • Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 2016;152:745-761

 

2016

  • Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 2016;152:745-761
  • Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium. Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis
  • Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. IGF2 Is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models. Gastroenterology 2016; 151:1192-1205
  • Villanueva A, Luedde T. The transition from inflammation to cancer in the liver. Clinical Liver Disease 2016 (in press)
  • D’Avola D, Labgaa I, Villanueva A. Natural history of non-alcoholic steatohepatitis / non-alcoholic fatty liver disease – hepatocellular carcinoma: Magnitude of the problem from a Hepatology clinic perspective. Clinical Liver Disease 2016 (in press)
  • Craig AJ, Villanueva A. Molecular-based signatures in hepatocellular carcinoma. Hepatology 2016; 63(6): 2018
  • Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol 2016 (in press)
  • Wiegand J, van Bömmel F, Duarte-Rojo A, Altamirano J, Abraldes JG, Villanueva A, Berg T. Clinical Trial Watch: Reports from the Liver Meeting, AASLD, San Francisco, November 2015. J Hepatol 2016;64:1428-45
  • Giovannoni R, Villanueva A. Circulating tumor cells and cholangiocarcinoma. Hepatology 2016;63:23-5.

 2015

  • Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Sole M, Domingo-Domenech J, Villanueva A, Llovet JM. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut 2015 (in press)
  • Sia D, Moeini A, Labgaa I, Villanueva A. The future of patient-derived tumor xenografts in cancer treatment. Pharmacogenomics 2015;16:1671-83.
  • Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015;149:1226-1239.
  • Gambato M, Villanueva A, Abraldes JG, Altamirano J, Forns X. Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. J Hepatol 2015;63:753-62.
  • Lujambio A, Villanueva A. The usual SASPects of liver cancer. Aging 2015 (in press)
  • Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015 (in press).
  • Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, Altunkaynak C, Sangiovanni A, Ivarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, Llovet JM, Hoshida Y, Friedman SL. Gut 2015 (in press)
  • Labgaa I, Villanueva A. Liquid biopsy in liver cancer. Discov Med 2015; 19:263-73
  • Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Genomic landscape of hepatocellular carcinoma: from malignant transformation to therapeutic targets. Nat Genet 2015;47(5):505-511.
  • Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Mendez-Gonzalez J, Imbeaud S, Letouze E, Hernandez-Gea V, Cornella H, Pinyol R, Sole M, Fuster J, Zucman-Rossi J, Mazzaferro V, Esteller M, Llovet JM. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology 2015;61(6):1945-56.
  • Nault JC, Villanueva A. Intra-tumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin Cancer Res 2015;21(8):1786-8.

2014

  • Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesus M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM. Gastroenterology 2014;148(4):806-818.
  • Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt A, Newell DR, Rose J, Manas DM, Shapiro GI, Curtin N, Reeves H. DNA- PK – a candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin Cancer Res 2014;21(4):925-33.
  • King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 2014 (in press).
  • Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, Senbanerjee S, Ukomadu C, Llovet JM, Sadler KC. UHRF1 as an oncogene in hepatocellular carcinoma. Cancer Cell 2014;25(2):196-209
  • Pennycuick A, Suddle AR, Villanueva A. Transplantation for hepatocellular carcinoma. Worth waiting for? Liver Transpl 2014;20:871-3.
  • Villanueva A, Llovet JM. Mutational landscape of HCC – the end of the beginning. Nat Rev Clin Oncol 2014;11:73-4.

2013

  • Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 2013;145(1):176-87.
  • Sia D, Alsinet C, Newell P, Villanueva A. VEGF signaling in cancer treatment. Curr Pharm Des 2013;20:2834-42
  • Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene-expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144(5):1024-30.
  • Alsinet C, Cornella H, Villanueva A. Genetically engineered mouse models: future tools to predict clinical trial results in oncology? Future Oncol 2013;9(6):767-70
  • Villanueva A. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. J Hepatol 2013;59(2):392-5.
  • Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia- Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals two subclasses with distinct clinical outcome. Gastroenterology 2013;144(4):829-40.
  • Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol 2013;28:1193-9.
  • Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Sole M, Lee WL, Kuka TP, Moriarity BS, Villanueva A, Dupuy AJ, Riordan JD, Bell JB, T Silverstein KA, Llovet JM, Largaespada DA. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 2013;57:120-30.

2012

  • Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Sole M, Thung S, Stanger BZ, Llovet JM. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012;143(6):1660-1669.
  • Lachenmayer A, Savic R, Alsinet C, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz ME, Friedman SL, Llovet JM. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012;18(18):4997-5007.
  • Villanueva A, Llovet JM. Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology 2012;56(6):2416-9.
  • Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastro Hepat 2012;10(1):34-42.
  • Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, Hannivoort R, Narla G, Llovet JM, Thung S, Friedman SL. Enhanced hepatocarcinogenesis in mouse models and human HCC by coordinate KLF6 depletion and increased mRNA splicing. Hepatology 2012;56(4):1361- 70.
  • Villanueva A, Llovet JM. Second-line therapies in HCC: emergence of resistance to sorafenib. Clin Cancer Res 2012;18:1824-26.
  • Villanueva A, Forns X, Llovet JM. Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. J Hepatol 2012;57:213-214.
  • Alsinet C, Villanueva A, Llovet JM. Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. J Hepatol 2012;56:1198-200.
  • Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Bruix J, Mazzaferro V, Friedman SL, Llovet JM. Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012;56:1343-50.
  • Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A. Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 2012;39(4):473-85.
  • Toffanin S, Sia D, Villanueva A. microRNAs: new ways to block tumor angiogenesis? J Hepatol 2012;57(3):490-1.
  • Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for hepatocellular carcinoma? J Hepatol 2012;57:453-454.

2011

  • Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung S, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-12.
  • Sia D, Villanueva A. Signaling pathways in hepatocellular carcinoma. Oncology 2011;81:18-23
  • Villanueva A, Hoshida Y, Llovet JM. Hepatocellular carcinoma enters the sequencing era. 
Gastroenterology 2011;141:1943-5.
  • Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM. Gastroenterology 2011;140:1618-28
  • Villanueva A, Hoshida Y. Depicting the role of TP53 in hepatocellular carcinoma progression. 
J Hepatol 2011;55:724-51.
  • Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26.
  • Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31.
  • Cornella H, Alsinet C, Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. 
Alcohol Clin Exp Res 2011;35:821-5.
  • Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, Llovet JM, Friedman SL. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitu- late human hepatocellular carcinoma, associated with p53 pathway deregulation. Hepatology 2011;54:522-31.

2010

  • Tovar V, Alsinet C, Villanueva A, Chiang DY, Sole M, Thung S, Moyano S, Toffanin S, Minguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM. IGF pathway deregulation in early HCC and pre-clinical efficacy of blocking IGF1R. J Hepatol 2010;52:550-559.
  • Toffanin S, Villanueva A, Llovet JM. miRNA delivery: emerging therapy for HCC. Gastroenterology 2010;138:1202-1204.
  • Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel 
molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28
  • Cornella H, Villanueva A. Genomic tracing of the elusive liver cancer ancestor. J Hepatol 
2010;53:578-9.
  • Zender L, Villanueva A, Tovar V, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-29.
  • Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: Genomic Prognostic Markers. Clin Cancer Res 2010;16:4688-94.
  • Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advances. Semin Liver Dis 2010;30:35-51.
  • Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24:725-34.

2009

  • Keng V, Villanueva A, Chiang D, Starr T, Silverstein K, Akagi K, Tessarollo L, Matise I, Sarver A, Powers S, Lowe S, Collier L, Dupuy A,Jenkins N,. Copeland N, Llovet JM, Largaespada DA. LE: A condicional transposon-based insertional mutagenesis system for modeling human cancer in mice. Nat Biotechnol 2009;27:264-74.
  • Villanueva A, Savic R, Llovet JM. Lymphotoxins: new targets for hepatocellular carcinoma. Cancer Cell 2009;16:272-3.
  • Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009;25:186-94.
  • Yoo B, Emdad L, Su Z, Villanueva A, Chiang DY, Mills AS, Waxman S, Fisher R, Llovet JM, Fisher P, Sarkar D. Astrocyte elevated gene–1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009;19:465-77.
  • Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel M, Thung S, Alsinet C, Tovar V, Hoshida Y, Bruix J, Roayaie S, Mazzaferro V, Schwartz M, Friedman S, Llovet JM. Ras pathway activa- tion in hepatocellular carcinoma and anti-tumoral effect of double blockage with Sorafenib and Rapamycin in vivo. J Hepatol 2009;51:725-33.
  • Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009;3:101-3.
  • Hoshida Y, Nijman S, Kobayashi M, Chan J, Jean- Brunet P, Chiang DY, Villanueva A, Newell P,Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.

2008

  • Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83.
  • Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang D, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan J, Ikeda K, Hashimoto M, Watanabe G, Roayaie S, Schwartz M, Thung S, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression profiles of adjacent liver predict outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-04.
  • Newell P, Villanueva A, FriedmanS, Koike K, and Llovet JM. Experimental models in hepa- tocellular carcinoma. J Hepatol 2008;48:858-79.
  • Newell P, Villanueva A, Llovet JM. Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. J Hepatol 2008;49:1-5.
  • Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Akita K, Shira- sawa S, Sasazuki T, Margignetti J, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008;134:1521-31.
  • Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF signaling. Mol Cancer Ther 2008;7:3129-40.
  • Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol 2008;20:444-45.
  • Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, Leblanc AC, Donovan DJ, Thung SN, Sole M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-88.

2007 & before

  • Villanueva A, Newell P, Chiang D, Friedman S, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55-76.
  • Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma: an update analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47.
  • Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl 2006;12:1747-54.
  • Llovet JM, Chen Y, Wurmbach W, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular sig- nature to discriminate dysplastic nodules and early hepatocellular carcinoma in HCV-cirrhosis. Gastroenterology 2006;6:1758-67.
  • Dominguez-Munoz JE, Villanueva A, Larino J, Mora T, Barreiro M, Iglesias-Canle J, Iglesias- Garcia J. Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. Eur J Gastroenterol Hepatol 2006;18:79-83.
  • Castroagudin JF, Delgado M, Villanueva A, Bustamante M, Martinez J, Otero E, Tome S, Martinez SM, Segade FR, Conde R, Dominguez-Munoz E, Varo E. Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. Transplant Proc 2005;37:3871-3.
  • Villanueva A, Dominguez-Munoz JE, Mearin F. Update in the therapeutic management of irritable bowel syndrome. Dig Dis 2001;19:244-50.